LinqMed

Executive Summary

LinqMed Inc., a Japanese radiopharmaceutical startup founded in 2022, is pioneering ‘visible’ anti-cancer treatments using copper-64 (⁶⁴Cu) radioisotopes. The company’s theranostic platform integrates diagnostic imaging and targeted therapy into a single agent, enabling personalized treatment for intractable cancers while minimizing unnecessary interventions. By leveraging Cu-64’s ideal half-life (12.7 hours) and dual beta-plus and beta-minus decay, LinqMed aims to overcome limitations of existing isotopes like gallium-68 or lutetium-177. Currently at preclinical stage, the company is developing candidates for multiple solid tumors and has established research collaborations in Japan. While still early-stage, LinqMed addresses a high-demand niche in radiotheranostics, a market projected to grow significantly. The company’s success hinges on validating its platform in vivo and securing partnerships for clinical translation and manufacturing. With Japan’s supportive regulatory framework for novel radiopharmaceuticals and an experienced team, LinqMed represents a promising opportunity in precision oncology, albeit at elevated risk typical of preclinical ventures.

Upcoming Catalysts (preview)

• Q1 2027Completion of IND-enabling preclinical studies80% success
• Q3 2026Series A financing round70% success
• H2 2027First-in-human clinical trial initiation55% success